NEW YORK, Jan. 3, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB:TAUG) or (“Tauriga” or “the Company”), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has a received a comprehensive update from Immunovative Therapies Ltd. (“ITL”) highlighting some potentially positive developments. On January 02, 2014, the Company was notified that ITL will relaunch clinical trials in Thailand (metastatic cancer) and Israel (liver cancer) later this month. Additionally ITL has definitive plans to launch a pivotal Phase II/III trial (breast cancer) during April-May, 2014.
Help employers find you! Check out all the jobs and post your resume.
